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1. We agree that hip fracture is important, and ideally any validation study should consider a separate analysis for hip fracture. However the number of hip fractures was small (n=20) in our study and thus was not sufficient for a full stratified analysis. Despite these small numbers, the concordance for hip fracture prediction between FRAX and Garvan nomogram predicted risk of hip fracture was 0.73 for women and 0.29 for men. 2. The concordance between FRAX and Garvan nomogram predicted probabilities of fracture was generally higher in women than in men. For instance, for any osteoporotic fracture, the correlation between the two algorithms was 0.82 in women but only 0.20 for men. 3. Determining an appropriate risk threshold for treatment depends, among other things, on the effectiveness of treatment and risk-benefit considerations. The latter are, in turn, dependent on the wealth and healthcare system of a country. The National Osteoporosis Foundation recommended thresholds [3] of 20% for any fracture and 3% for hip fracture are relevant to the US setting but not necessarily to non-US populations.
We consider that treatment thresholds need further country-specific studies.
The assessment of fracture risk has entered a new era with individualized or absolute risk being the preferred approach. However, the predictive performance of any algorithm should be thoroughly evaluated in relevant cohorts before it is implemented in clinical settings. We thank our colleagues for their thoughtful contribution to the on-going discussion on fracture risk assessment.
